Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations
Anna Ferrari(University of Bologna), Giovanni Martinelli(University of Bologna), Delia Cangini(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giovanni Schininà(Policlinico Universitario di Catania), Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Sebastiano Cosentino(Ospedale Cannizzaro), Chiara Domizio(University of Ferrara), Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giuseppe Milone(University of Catania), Annalisa Condorelli(Ospedale Papa Giovanni XXIII), Salvatore Leotta(Policlinico Universitario di Catania), Marta Pugliese(Policlinico Universitario di Catania), Eugenio Fonzi(University of Bologna)
Cited by 32
Related Papers
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
|The Lancet Oncology|2019|486
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
|Blood|2011|460
Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study
|Journal of Clinical Oncology|2007|374